Thymoma-associated panencephalitis: a newly emerging paraneoplastic neurologic syndrome

Lynda Adaobi Nwabuobi, Jacob Christian Pellinen, Thomas Mark Wisniewski

Department of Neurology, NYU Langone Medical Center, New York University School of Medicine, New York, NY 10016, USA.

Correspondence to: Dr. Lynda Adaobi Nwabuobi, Department of Neurology, NYU Langone Medical Center, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. E-mail: lynda.nwabuobi@med.nyu.edu

How to cite this article: Nwabuobi LA, Pellinen JC, Wisniewski TM. Thymoma-associated panencephalitis: a newly emerging paraneoplastic neurologic syndrome. Neuroimmunol Neuroinflammation 2017;4:117-23.

ABSTRACT

Recently, a few case reports of thymoma-associated panencephalitis (TAPE) have brought to light a disease entity that has not been fully characterized. Literature review of TAPE reveals an array of associated neuronal antibodies, with varied responses to thymomectomy with or without immunotherapy. This report describes a case of TAPE and proposes that the GABA_A receptor antibody is a potential target antigen driving the immune process in this disease entity. Treatment-wise, early thymomectomy consistently improves the overall course of disease. Further study of such cases will be critical in clarifying the mechanisms of disease, improving early diagnosis, and developing targeted approaches to treatment.

INTRODUCTION

Thymomas are often associated with paraneoplastic neurologic syndromes (PNS) as they have the propensity to express different autoantibodies against neuronal antigens, many of which clinical pathogenicity have not been established. [1,2] Quite rarely, thymomas have been associated with limbic encephalitis, a well-characterized neurological syndrome that presents with memory impairment, behavioral changes, and
seizures.[3] The target antigen when it manifests in thymomas is largely unknown, however, some cases have reported antibodies to α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, leucine-rich glioma inactivated 1 protein (LGI1), contactin associated protein 2 (Caspr2), and glutamic acid decarboxylase (GAD).[4] A new entity has been described in a few cases of paraneoplastic encephalitis associated with thymomas, with lesions extending beyond the mesial temporal lobe structures.

CASE REPORT

A 35-year-old man presented with a 2-week history of seizures, poor appetite, generalized headaches and nausea. Neurologic assessment revealed poor attention, orientation and memory loss, without clinical seizures. Computed tomography head showed multiple cortical hypodensities, prompting an magnetic resonance imaging (MRI) brain, which revealed multiple foci of cortical hyperintensity involving the medial left frontal cortex, the right dorsal aspect of the insula and adjacent right temporal cortex as well as the posterior left temporal cortical medullary junction and the medial posterior left temporal cortex and lateral cortex [Figure 1]. Electroencephalogram revealed hyperexcitability over the right temporal region and frequent focal seizures and he was empirically treated with IV acyclovir, lacosamide and levetiracetam. Cerebral spinal fluid (CSF) analysis revealed protein of 0.51 g/L, glucose of 3.5 mmol/L, 3 × 10^6/L red blood cells and 9 × 10^6/L white blood cells (76% lymphocytes, 18% monocytes, 6% neutrophils). CSF and serum studies were also positive for neuronal antibodies to GAD [3.93 nmol/L in the CSF (normal < 0.02 nmol/L), > 250.0 kIU/L in the serum (reference range 0-5 kIU/L)], VGKC-complex antibodies [158 pmol/L in the CSF (reference range 0-31 pmol/L), 98 pmol/L in the serum (reference range 0-31 pmol/L)], CRMP5 (reflex titer < 1:240; positive western blot), and AchR [binding antibody 17.5 nmol/L in the CSF (normal < 0.02 nmol/L), and 142.8 nmol/L in the serum (reference range 0.0-0.4 nmol/L)]. Additionally, serum studies revealed presence of systemic antibodies to thyroperoxidase (37.8 kIU/L, reference range 0-5.5 kIU/L), thyroglobulin (372.2 kIU/L, reference range 0-5 kIU/L), Ro/SSA (6.8 AI, reference range < 1 AI), and an ANA titer of 80 (reference range 0-40) with a nucleolar pattern. A paraneoplastic syndrome was suspected, and full body imaging revealed a large multilobulated right anterior mediastinal mass, interfacing multiple right-sided mediastinal structures and invading the...
bilateral lung apices. This mass was later confirmed to be a metastatic type B2, stage III thymoma via biopsy and after resection [Figure 2]. The patient was treated with intravenous methylprednisolone (1 g/day for 10 days) followed by 0.4 g/kg daily immunoglobulin (IVIG) for total of 4 days. He had significant improvement in his mental status with the first dose of steroids. Repeat imaging 2 weeks after initial presentation showed improvement in the cortical lesions, specifically, decrease in the abnormal fluid-attenuated inversion recovery (FLAIR) hyperintensities [Figure 1]. Further treatment included chemotherapy with cisplatin, doxorubicin, and cyclophosphamide given the invasive nature of the thymoma. Prior to thymomectomy, his course was complicated by gastrointestinal dysmotility syndrome thought to be a result of his paraneoplastic syndrome. He underwent a successful thymomectomy with complete resection approximately 3 months after initial presentation, and continued to improve thereafter.

DISCUSSION

Based on literature review, our patient is one of the very few reported cases of thymoma-associated panencephalitis (TAPE). These cases highlight the similar neurological symptoms at presentation -- seizures, confusion, and memory loss being the most common -- with a constellation of positive antibodies and different responses to treatment [Table 1]. The similar presentations and MRI findings in these patients support TAPE as a distinct disease entity and autoimmune disorder. Our case was unique as our patient was found to have multiple neuronal and non-neuronal antibody responses and had a drastic improvement in his clinical symptoms with just immunotherapy, unlike other cases that showed improvement after thymomectomy and/or extensive immunotherapy. In order to further characterize TAPE as a paraneoplastic syndrome, antibody associations need to be elicited.

In reviewing the prior reported cases, these patients can have a variety of autoantibodies as seen in Table 1, the most common being AchR, present in 9 of 16 cases, with 5 having symptoms of myasthenia gravis (MG). This is not surprising as up to 37% of patients with thymic tumors but without MG have been reported to have positive antibody titers to AchR.[5] Voltage-gated potassium channel (VGKC) was the 2nd most common antibody seen in 5 patients. It has been proven that the antibodies to VGKC actually target the associated proteins LGI1 and Caspr2, and not the channel itself, therefore rendering the term, “antibodies to VGKC” obsolete.[6] Antibodies to LGI1 and Caspr2 were present in 3 and 1 of the patients, respectively. In reviewing the prior reported cases, these patients can have a variety of autoantibodies as seen in Table 1, the most common being AchR, present in 9 of 16 cases, with 5 having symptoms of myasthenia gravis (MG). This is not surprising as up to 37% of patients with thymic tumors but without MG have been reported to have positive antibody titers to AchR.[5] Voltage-gated potassium channel (VGKC) was the 2nd most common antibody seen in 5 patients. It has been proven that the antibodies to VGKC actually target the associated proteins LGI1 and Caspr2, and not the channel itself, therefore rendering the term, “antibodies to VGKC” obsolete.[6] Antibodies to LGI1 and Caspr2 were present in 3 and 1 of the patients, respectively. Both CRMP-5 and GAD were occasionally present among the cases. The presence of GAD antibodies in thymoma is associated with stiff person syndrome and unlikely to manifest as encephalitis.[1] CRMP-5 has been shown to be a marker of immune response initiated by thymomas in different PNS, and therefore, may not be neuropathogenic.[7] Antibodies against Hu, Ri, and Yo were the least common, absent in 50% of the patients. Review of associated antibodies in these previously reported cases does not show a clear pattern, and it is unclear which antibodies are actually pathologic and which ones are incidental. Of significant importance, Petit-Pedrol et al.[8] recently reported 6 patients who presented very similarly to

![Figure 2: Computed tomography chest showing large right mediastinal mass. Contrast-enhanced computed tomography images (A: axial; B: coronal), showing a large multilobulated right anterior mediastinal mass measuring 6.0 cm x 4.7 cm in transverse dimension by approximately 13 cm in craniocaudal dimension. There was found to be mass effect with mild compression of the right atrium and superior vena cava (though patent). Thymoma was suspected, and proven later on biopsy]
### Table 1: Literature review of cases of thymoma-associated panencephalitis

<table>
<thead>
<tr>
<th>Paper</th>
<th>Year</th>
<th>Age</th>
<th>Gender</th>
<th>Neurological symptoms</th>
<th>Antibodies (+)</th>
<th>Antibodies (-)</th>
<th>Cell surface vs. onconeuronal Ab</th>
<th>Treatment</th>
<th>Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>This case</td>
<td>2015</td>
<td>35</td>
<td>M</td>
<td>Seizures, confusion, agitation, decreased to no verbal response</td>
<td>GAD, VGKC-complex, AchR (binding), CRMP5</td>
<td>Hu, Ri, Yo, VGCC, NMDA, GABA-B, AMPA, ANNA-3, anti-glia nuclear, PCA-2, PCA-Tr, amphiphysin, AchR (ganglionic neuronal)</td>
<td>Cell surface/onconeuronal Ab</td>
<td>Steroids, IVIG, chemotherapy, thymomectomy</td>
<td>1 day after steroids</td>
</tr>
<tr>
<td>Reginold et al.</td>
<td>2016</td>
<td>47</td>
<td>M</td>
<td>Psychosis, seizures, ocular weakness</td>
<td>-</td>
<td>Hu, Ri, Yo</td>
<td></td>
<td>Steroids, thymomectomy</td>
<td>Over 4 weeks after steroids and thymomectomy</td>
</tr>
<tr>
<td>Simabukuro et al.</td>
<td>2015</td>
<td>45</td>
<td>F</td>
<td>MG; 8 years later, memory loss, behavioral changes</td>
<td>GABA-A, LGI1, AchR</td>
<td>GABA-B, AMPA, NMDA, Caspr2, GlyR, mGLUR5, mGLUR1, GAD</td>
<td>Cell surface</td>
<td>Steroids, PLEX, thymomectomy</td>
<td>Improved after initial treatment, with recurrence 3 months later and improvement after removal of thymic met</td>
</tr>
<tr>
<td>Aragaki et al.</td>
<td>2015</td>
<td>66</td>
<td>F</td>
<td>Leg cramping/inability to walk, seizures</td>
<td>-</td>
<td>AchR</td>
<td></td>
<td>Thymomectomy</td>
<td>6 days after thymomectomy and doing fairly well 7 months later</td>
</tr>
<tr>
<td>Aysal et al.</td>
<td>2013</td>
<td>43</td>
<td>M</td>
<td>Seizures, MG (bulbar symptoms)</td>
<td>AchR</td>
<td>VGKC-complex</td>
<td>Cell surface</td>
<td>IVIG, pyridostigmine</td>
<td>MG symptoms improved after IVIG, then seizures improved after thymomectomy; MRI normal 2 years later and patient doing well Improvement in mental status 10 days after thymomectomy and almost complete recovery 3 months later; asymptomatic 2 years later</td>
</tr>
<tr>
<td>Suh et al.</td>
<td>2013</td>
<td>42</td>
<td>F</td>
<td>Memory loss, voice change, ptosis, agitation, drowsiness</td>
<td>AchR</td>
<td>Hu, Ri, Yo</td>
<td>Cell surface</td>
<td>Thymomectomy</td>
<td>MG symptoms improved after IVIG, then seizures improved after thymomectomy; MRI normal 2 years later and patient doing well Improvement in mental status 10 days after thymomectomy and almost complete recovery 3 months later; asymptomatic 2 years later</td>
</tr>
<tr>
<td>Miyazaki et al.</td>
<td>2012</td>
<td>46</td>
<td>M</td>
<td>MG; 4 years later, aphasia, seizures, delirium, visual hallucinations</td>
<td>AchR, GABA-A, LGI1</td>
<td>-</td>
<td>Cell surface</td>
<td>Thymomectomy, steroids, IVIG</td>
<td>Status epilepticus resolved 2 weeks after treatment, but cognitive impairment and psychological symptoms remained</td>
</tr>
<tr>
<td>Erkmen et al.</td>
<td>2011</td>
<td>61</td>
<td>F</td>
<td>Seizures</td>
<td>LGI1</td>
<td>-</td>
<td>Cell surface</td>
<td>IVIG, steroids, thymomectomy</td>
<td>Over 4 weeks prior to thymomectomy</td>
</tr>
<tr>
<td>Werry et al.</td>
<td>2009</td>
<td>32</td>
<td>M</td>
<td>Vertigo, diplopia, nystagmus, left hand clumsiness, olfactory disturbances, gait ataxia, myoclonic jerking, memory loss, hallucinations, anxiety; 1yr later, MG</td>
<td>CRMP5; later AchR</td>
<td>VGKC-complex, Hu, Ri, Yo, Ma-2, amphiphysin</td>
<td>Cell surface/onconeuronal Ab</td>
<td>No improvement after thymomectomy, steroids, IVIG, and partial PLEX until 4 months later; 1 year later, developed MG, which completely resolved with immunosuppression</td>
<td></td>
</tr>
<tr>
<td>Paper</td>
<td>Year</td>
<td>Age</td>
<td>Gender</td>
<td>Neurological symptoms</td>
<td>Antibodies (+)</td>
<td>Antibodies (-)</td>
<td>Cell surface vs. onconeuronal Ab</td>
<td>Treatment</td>
<td>Improvement</td>
</tr>
<tr>
<td>------------------------</td>
<td>------</td>
<td>-----</td>
<td>--------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hammoud et al.</td>
<td>2009</td>
<td>43</td>
<td>F</td>
<td>MG, 4yrs later, seizure, confusion, aphasia</td>
<td>AchR, Hu, Ri, Yo, AChR binding, modulating, VGKC-complex, VGCC-complex</td>
<td>AchR, Hu, Ri, Yo, AChR binding, modulating, VGKC-complex, VGCC-complex</td>
<td>Cell surface, onconeuronal Ab</td>
<td>Steroids, IVG, 1 cycle of chemotherapy</td>
<td>Some improvement of speech and cognitive function, but levels 2 weeks after steroids were fairly low but improved by 1 month</td>
</tr>
<tr>
<td>Okita et al.</td>
<td>2007</td>
<td>33</td>
<td>F</td>
<td>Seizure, later, confusion, decreased visuospatial and apathy</td>
<td>AchR, Hu, Ri, Yo, AChR binding, modulating, VGKC-complex, VGCC-complex</td>
<td>AchR, Hu, Ri, Yo, AChR binding, modulating, VGKC-complex, VGCC-complex</td>
<td>Cell surface, onconeuronal Ab</td>
<td>Thymomectomy, steroids</td>
<td>Improved initially with no treatment, partial improvement of mental status after steroids</td>
</tr>
<tr>
<td>Ohshita et al.</td>
<td>2006</td>
<td>59</td>
<td>F</td>
<td>Memory impairment, agitation, later, spasm and rigidity</td>
<td>AchR, Hu, Ri, Yo, AChR binding, modulating, VGKC-complex, VGCC-complex</td>
<td>AchR, Hu, Ri, Yo, AChr binding, modulating, VGKC-complex, VGCC-complex</td>
<td>Cell surface, onconeuronal Ab</td>
<td>Thymomectomy, chemotherapy</td>
<td>Improved initially with no treatment, partial improvement of mental status after steroids</td>
</tr>
<tr>
<td>Vernino et al.</td>
<td>2002</td>
<td>34</td>
<td>F</td>
<td>Vertigo, tinnitus, memory impairment, later, spasm and rigidity</td>
<td>AchR, Hu, Ri, Yo, AChR binding, modulating, VGKC-complex, VGCC-complex</td>
<td>AchR, Hu, Ri, Yo, AChr binding, modulating, VGKC-complex, VGCC-complex</td>
<td>Cell surface, onconeuronal Ab</td>
<td>PLEX, plasmapheresis, IVG, steroids, PLEX</td>
<td>Worsened after thymomectomy, improved initially with no treatment to steroids, some improvement of symptoms 2 months after steroids</td>
</tr>
<tr>
<td>Rickman et al.</td>
<td>2000</td>
<td>55</td>
<td>M</td>
<td>Dysarthria, seizure, confusion, short term memory impairment, later, apathy</td>
<td>AchR, Hu, Ri, Yo, AChR binding, modulating, VGKC-complex, VGCC-complex</td>
<td>AchR, Hu, Ri, Yo, AChr binding, modulating, VGKC-complex, VGCC-complex</td>
<td>Cell surface, onconeuronal Ab</td>
<td>Thymomectomy, PLEX, steroids</td>
<td>Worsened after thymomectomy, improved initially with no treatment to steroids, some improvement of symptoms 2 months after steroids</td>
</tr>
</tbody>
</table>

GAD: glutamic acid decarboxylase; VGKC: voltage gated potassium channel; AchR: acetylcholine receptor; CRMP-5: collapsing response mediator protein 5; VGCC: voltage gated calcium channel; NMDAR: N-methyl-D-aspartate receptor; GABAA-R: gamma-aminobutyric acid type A receptor; AMPAR: α-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor; LGI1: leucine-rich, glioma inactivated 1; Caspr2: contactin associated protein 2; GlyR: glycine receptor; mGLUR5: metabotropic glutamate receptor 5; mGLUR1: metabotropic glutamate receptor 1; ANNA-3: anti-neuronal nuclear antibody 3; PCA-1, 2, Tr: purkinje cell antibody 1, 2, Tr; PLEX: plasmapheresis; IVG: intravenous globulin; ELE: extralimbic encephalitis; MG: myasthenia gravis.
our patient (behavioral/cognitive changes, seizures, multifocal T2/FLAIR lesions) with high titer CSF and serum antibodies to GABA$_A$R. These patients did not have evidence of thymoma, however, did have other evidence of immune dysregulation, including the presence of other antibodies. Most importantly, the GABA$_A$R antibody was shown to have pathogenic effects on the antigen, specifically, downregulation of receptors in cultured neurons and patients usually responded to therapy. Furthermore, Okhawa et al. retested the sera of 2 patients previously with TAPE via a nonbiased proteomic method and identified antibodies to GABA$_A$R. Our patient was not tested for this antibody, however, his clinical findings, brain imaging, and response to therapy are suggestive of GABA$_A$R associated panencephalitis.

One of the setbacks in managing TAPE is early recognition as there are so few cases reported. PNS associated with antineuronal cell surface antibodies are often highly responsive to treatment, while those with onconeural antibodies have a generally poor response. Review of the cases shows responses to treatments differed without any clear correlation to antibody types. Every patient received thymectomy with partial or full response followed by a combination of steroids, plasmapheresis and/or IVIG. This suggests that early surgical removal of tumors with or without immunotherapy could provide a good chance of recovery from disease. Albeit, the presence of both cell-surface and onconeural antibodies in our patient may indicate a poor prognosis despite his initial rapid improvement.

Authors’ contributions
Concept, literature search, preparation, editing and revision of manuscript: L. Nwabuobi
Patient data and imaging acquisition, editing and revision of manuscript: J. Pellinen
Supervision and revision of manuscript: T. Wisniewski

Financial support and sponsorship
None.

Conflicts of interest
There are no conflicts of interest.

Patient consent
Verbal consent was obtained from the patient.

Ethics approval
Not applicable.

REFERENCES


